|Author (Corporate)||European Commission: DG Trade|
|Series Title||Official Journal of the European Union|
|Series Details||L 104, Pages 52/54|
|Content Type||Legislation, News|
Implementing Regulation (EU) 2021/521 adopted by the European Commission on 24 March 2021, introducing changes to the transparency and authorisation mechanism for COVID-19 vaccine exports.
The European Commission adopted in January 2021 the Implementing Regulation (EU) 2021/111, aimed at making exportation of COVID-19 vaccines as well as active substances, including master and working cell banks, used to manufacture these vaccines, subject to the production of an export authorisation. This export authorisation mechanism only applies to exports from companies with which the EU has concluded Advance Purchase Agreements (APAs). In March 2021, Implementing Regulation (EU) 2021/442 introduced an extension to this measure.
This Implementing Regulation introduces the principles of reciprocity and proportionality as new criteria to be considered for authorising exports under this mechanism. It was adopted by the European Commission on 24 March 2021 and published in the Official Journal on the following day.
|Subject Categories||Health, Trade|
|Subject Tags||Export | Import Controls, Medicines | Medical Devices|
|International Organisations||European Union [EU]|